https://doi.org/10.1200/jco.1998.16.4.1310 · 
Full text
Journal: Journal of Clinical Oncology, 1998, №4, p.1310-1317
Publisher: American Society of Clinical Oncology (ASCO)
Authors:
- M Al-Sarraf
- M LeBlanc
- P G Giri
- K K Fu
- J Cooper
- T Vuong
- A A Forastiere
- G Adams
- W A Sakr
- D E Schuller
- J F Ensley
Abstract
<jats:sec>PURPOSE The Southwest Oncology Group (SWOG) coordinated an Intergroup study with the participation of Radiation Therapy Oncology Group (RTOG), and Eastern Cooperative Oncology Group (ECOG). This randomized phase III trial compared chemoradiotherapy versus radiotherapy alone in patients with nasopharyngeal cancers. </jats:sec><jats:sec>MATERIALS AND METHODS Radiotherapy was administered in both arms: 1.8- to 2.0-Gy/d fractions Monday to Friday for 35 to 39 fractions for a total dose of 70 Gy. The investigational arm received chemotherapy with cisplatin 100 mg/m2 on days 1, 22, and 43 during radiotherapy; postradiotherapy, chemotherapy with cisplatin 80 mg/m2 on day 1 and fluorouracil 1,000 mg/m2/d on days 1 to 4 was administered every 4 weeks for three courses. Patients were stratified by tumor stage, nodal stage, performance status, and histology. </jats:sec><jats:sec>RESULTS Of 193 patients registered, 147 (69 radiotherapy and 78 chemoradiotherapy) were eligible for primary analysis for survival and toxicity. The median progression-free survival (PFS) time was 15 months for eligible patients on the radiotherapy arm and was not reached for the chemo-radiotherapy group. The 3-year PFS rate was 24% versus 69%, respectively (P < .001). The median survival time was 34 months for the radiotherapy group and not reached for the chemo-radiotherapy group, and the 3-year survival rate was 47% versus 78%, respectively (P = .005). One hundred eighty-five patients were included in a secondary analysis for survival. The 3-year survival rate for patients randomized to radiotherapy was 46%, and for the chemoradiotherapy group was 76% (P < .001). </jats:sec><jats:sec>CONCLUSION We conclude that chemoradiotherapy is superior to radiotherapy alone for patients with advanced nasopharyngeal cancers with respect to PFS and overall survival. </jats:sec>
Publications that cite this publication
Adjuvant High-Dose Rate Brachytherapy After Chemoradiation for Treatment of Early T-Stage Nasopharyngeal Carcinoma
Jiade J. Lu, Thomas Shakespeare, Boon Cher Goh, Chua Eu Tiong, Michael Back, Rahul Mukherjee, Christopher J. Wynne, Kim Siang Luke Tan
https://doi.org/10.1097/01.coc.0000046592.90778.fc
2004, American Journal of Clinical Oncology, №2, p.132-135
Scopus
WoS
Crossref citations:2
Tension Pneumocephalus Related to Radiotherapy for Nasopharyngeal Carcinoma
Esther Jimenez-Jimenez, Sebastià Sabater Martí, M. Victoria Villas
https://doi.org/10.1155/2014/327380 · Full text
2014, Case Reports in Oncological Medicine, p.1-4
Scopus
WoS
Crossref citations:1
Hyperfractionated Radiotherapy and Concomitant Cisplatin for Locally Advanced Laryngeal and Hypopharyngeal Carcinomas
Fernando Arias de la Vega, R. Vera García, Domínguez Domínguez, E. Villafranca Iturre, E. Martínez López, S. Miquelez Alonso, P. Romero, J. Medina Sola
https://doi.org/10.1097/01.coc.0000037741.09729.f4
2003, American Journal of Clinical Oncology, №6, p.550-557
Scopus
WoS
Crossref citations:6
Chemotherapy for nasopharyngeal carcinoma
MAC-NPC (Meta-Analysis of Chemother
https://doi.org/10.1002/14651858.cd004329
2003, Cochrane Database of Systematic Reviews
Crossref citations:0
Intensity-modulated radiotherapy alone compared with intensity-modulated radiotherapy plus concurrent chemotherapy in intermediate-risk nasopharyngeal carcinoma
Shufang Liao, Bin Zhang, Yixin Su, Yufei Pan, Jian Zhang, Zhenkai Ye, Rongjun Zhang, Xiangyun Kong, Guanjie Qin, Yunyan Mo, Xiaolan Ruan, Jian Liu, Chunqiao Gan, Jinxuan Dai, Ruyun Zhang, Guanhong Luo, Xiaofei Liao, Wei Jiang
https://doi.org/10.1007/s00066-024-02201-1 ·
2024, Strahlentherapie und Onkologie, №10, p.867-875
Scopus
WoS
Crossref citations:0
Early Nodal Response as a Predictor for Necessity of Functional Neck Dissection After Chemoradiation
Roy Vongtama, Michelle Lee, Brian Kim, Joel Sercarz, Kevin Lin, Marc A. Suchard, Steve E. Lee, Guy Juillard
https://doi.org/10.1097/00130404-200411000-00002 · Full text
2004, The Cancer Journal, №6, p.339-342
Scopus
WoS
Crossref citations:7
Nomogram for distant metastasis-free survival in patients with locoregionally advanced nasopharyngeal carcinoma
Huiyun Yang, Rongjun Zhang, Ruyun Zhang, Bin Zhang, Yuan Xie, Guanjie Qin, Yunyan Mo, Xiaolan Ruan, Wei Jiang
https://doi.org/10.1007/s00066-022-01926-1 ·
2022, Strahlentherapie und Onkologie, №9, p.828-837
Scopus
WoS
Crossref citations:1
Gemcitabine for patients with relapsed nasopharyngeal carcinoma
L. Mileshkin, D. Rischin
https://doi.org/10.1046/j.1445-5994.2002.00207.x
2002, Internal Medicine Journal, №5-6, p.275-276
Scopus
WoS
Crossref citations:0
Neurosurgical interventions for patients with nasopharyngeal carcinoma: a single institution experience
Ke Sai, Yong-gao Mou, Jing Zeng, Yan-chun Lv, Shao-yan Xi, Su Guan, Xiang-heng Zhang, Jian Wang, Chao Ke, Jian-gui Guo, Yin-sheng Chen, Zhong-ping Chen
https://doi.org/10.1186/1477-7819-11-227 · Full text
2013, World Journal of Surgical Oncology, №1
Scopus
WoS
Crossref citations:2
Plasma Epstein-Barr Virus MicroRNA BART8-3p as a Diagnostic and Prognostic Biomarker in Nasopharyngeal Carcinoma
Cheng Lin, Keyu Lin, Bin Zhang, Ying Su, Qiaojuan Guo, Tianzhu Lu, Yuanji Xu, Shaojun Lin, Jingfeng Zong, Jianji Pan
https://doi.org/10.1093/oncolo/oyac024 ·
2022, The Oncologist, №4, p.e340-e349
Scopus
WoS
Crossref citations:8
Find all citations of the publication
